Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: bioengineering

Progress in real science is steady, follows proper methodology and respects engineering safety. We live in an amazing world where medical progress is advancing rapidly, sadly we also have those willing to jump the gun hawking unproven experimental therapies without sufficient data.

Unproven therapies and people jumping the gun to make a quick buck are a plague in the aging research field. Real science is slow and methodical but ultimately gets results that ensure safe therapies can be deployed in the healthcare arena. At Lifespan.io we are passionate about supporting the progress of science that is conducted properly.

“The life science community should embrace the discrediting of unproven therapies promoted without data for economic gain, and instead focus on the promise of research held to the highest standards.”

#aging #crowdfundthecure

Read more

Luv it! Wait until we make the marriage of QC meets Synbio — QC for the infrastructure and communications, and Synbio makes us all connected.

Cambridge, MA (Scicasts) — Synthetic biology allows scientists to design genetic circuits that can be placed in cells, giving them new functions such as producing drugs or other useful molecules. However, as these circuits become more complex, the genetic components can interfere with each other, making it difficult to achieve more complicated functions.

MIT researchers have now demonstrated that these circuits can be isolated within individual synthetic “cells,” preventing them from disrupting each other. The researchers can also control communication between these cells, allowing for circuits or their products to be combined at specific times.

“It’s a way of having the power of multicomponent genetic cascades, along with the ability to build walls between them so they won’t have cross-talk. They won’t interfere with each other in the way they would if they were all put into a single cell or into a beaker,” says Edward Boyden, an associate professor of biological engineering and brain and cognitive sciences at MIT. Boyden is also a member of MIT’s Media Lab and McGovern Institute for Brain Research, and an HHMI-Simons Faculty Scholar.

Read more

There weren’t many people who had heard of bioterrorism before 9/11. But shortly after the September 11th terrorist attacks, a wave of anthrax mailings diverted the attention of the public towards a new weapon in the arsenal of terrorists—bioterrorism. A US federal prosecutor found that an army biological researcher was responsible for mailing the anthrax-laced letters, which killed 5 and sickened 15 people in 2001. The cases generated huge media attention, and the fear of a new kind of terrorist warfare was arising.

However, as with every media hype, the one about bioterrorism disappeared quickly.

But looking toward the future, I believe that we may not be paying as much attention to it as we should. Although it may be scary, we have to prepare ourselves for the worst. It is the only way we can be prepared to mitigate the damages of any harmful abuses if (and when) they arise.

Read more

In Brief:

Researchers at MIT have developed an easy-to-use “biological programming language” that allows genetic engineers (or just about anyone) to design biological circuits and “hack” the genomes of living cells.

The evolution of human technology has proceeded in lockstep with the biological evolution of our species. For millions of years we were content with our primitive Oldowan choppers and Acheulean bifaces; in the Neolithic, we started playing with more sophisticated tools, and the Bronze and Iron ages followed in quick succession.

Read more

ADELPHI, Md. — A U.S. Army Research Laboratory biotechnology scientist recently published an editorial article on the future directions of synthetic biology research to meet critical Army needs in the Synthetic Biology edition of the Journal of the American Chemical Society.

In the publication, Dr. Bryn Adams, who works in ARL’s Bio-Technology Branch, highlights examples of robust, tractable bacterial species that can meet the demands of tomorrow’s state-of-the-art in synthetic biology.

“ACS Synthetic Biology is the premier synthetic biology journal in the world, with a wide readership of biologists, chemists, physicists, engineers and computer programmers,” Adams said. “A publication in this journal allows me to challenge the leaders in the field to meet a Department of Defense specific need — the need for new synthetic biology chassis organisms, or host cell, and toolkits to build complex circuits in them.”

Read more

SRF Summer Scholars Program opens December 1st!

The SRF Summer Scholars Program offers undergraduate students the opportunity to conduct biomedical research to combat diseases of aging, such as cancer, Alzheimer’s, and Parkinson’s Disease. Under the guidance of a scientific mentor, each Summer Scholar is responsible for his or her own research project in such areas as genetic engineering and stem cell research. The Summer Scholars Program emphasizes development of both laboratory and communication skills to develop well-rounded future scientists, healthcare professionals, and policy makers. Students participating in the program will hone their writing skills via periodic reports, which are designed to emulate text scientists commonly must produce. At the end of the summer, students will have the opportunity to put all of their newly developed communication skills into practice at a student symposium.

Read more

When the future of genetic engineering arrived on Sebastian Cocioba’s doorstep, it was affixed to the back of a postcard from Austria with a little bit of packing tape.

Cocioba is a 25-year-old college dropout whose primary interest is tinkering with plant genetics in a lab he cobbled together from eBay. The lab is located in the spare bedroom of his parent’s lavish apartment in Long Island City, across the river from Manhattan. A few months ago, an internet friend from an online bio-hacking forum had sent him the lab’s latest addition: attached to that postcard was Crispr-Cas9.

Read more

Scientists have been working for decades on engineered viruses that can hunt down and get inside cancer cells, cause them to burst and spur the immune system to mop up whatever malignant cells might be left behind. Only one such treatment has successfully become an FDA-approved cancer treatment.

That one drug, from Amgen, isn’t selling much. But that small victory a year ago has emboldened others to go forward with their own ideas to advance this approach to cancer therapy, known as oncolytic virus therapy.

One of the aspiring players in the oncolytic virus field, Ottawa, Canada-based Turnstone Biologics, is announcing today it has raised $41.4 million in a Series B venture financing. The round was led by OrbiMed Advisors, and included F-Prime Capital Partners and a couple of existing investors, FACIT and Versant Ventures. The new money will add on to the $11.3 million Series A round from a year ago.

Read more